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ABSTRACT 
Asthma or exercise-induced bronchoconstriction (EIB) is highly prevalent in athletes 
and if untreated has the potential to impact on their health and performance. The 
condition can be diagnosed and managed effectively yet there is concern that the care 
afforded to elite athletes with this condition is often sub-optimal.  
In this respect, it is apparent that more could be done to protect athletes from developing 
airway dysfunction (e.g. by reducing exposure to irritant environments); that the 
diagnosis of asthma in athletes is often made without secure objective evidence and that 
athletes may be advised to reduce activity levels in order to improve symptoms. 
Moreover there appears to be poor surveillance of airway health in athletes when a 
diagnosis of asthma has been made. 
Overall this raises the question of who cares about athletes with asthma? The article 
that follows presents the case of why this is an important clinical area for physicians. 
The review provides an overview of asthma in athletes with the overall aim of ensuring 
that respiratory health in this unique population is optimised. 
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INTRODUCTION  
Asthma or exercise-induced bronchoconstriction (EIB) is highly prevalent in athletes 
(1, 2). Indeed it is estimated that up to half of athletes partaking in certain sports (e.g. 
swimming) have evidence of ‘asthma’ and as such it is the most frequently encountered 
chronic medical condition in Olympic athletes (3). 
On the face of it the condition would appear to be relatively simple to assess and manage. 
However, as this article will outline, this is often not the case and as a consequence 
there is legitimate concern that the care afforded to elite athletes with asthma is often 
suboptimal (4-8). 
Debate and controversy in the field of ‘asthma in athletes’ usually begins with a 
definition of the condition (9). In this respect, it is clear that many athletes with ‘asthma’ 
have respiratory symptoms confined to the exercise period alone and as such do not 
describe features characteristic of ‘classical’ asthma, e.g. nocturnal symptoms. In this 
population the condition may thus be better described by the physiologically descriptive 
term - exercise-induced bronchoconstriction (EIB); a transient airway narrowing 
occurring in association with exercise (10).  
Further difficulties arise when the criteria for a diagnosis of asthma / EIB are considered. 
It is now established that a ‘symptom-based’ approach to diagnosis is imprecise and 
that objective tests are required to ensure a diagnosis is secure (5, 11). Despite this it is 
apparent that even at the elite level of the sport, the diagnosis of asthma in an athlete is 
often based entirely on a clinical appraisal or with support from tests with poor 
diagnostic precision (e.g. peak flow monitoring) (4, 11).  
Moreover, when an athlete is diagnosed accurately there is often poor surveillance of 
their airway function following commencement of treatment, with the responsibility of 
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clinical follow-up often falling to a sports team doctor without respiratory medicine 
expertise; e.g. an orthopaedic specialist (12). This is remarkable given the impact of 
marginal physiological gains for performance in athletes competing at the elite or 
professional level.  
It is also now increasingly apparent that exercise hyperpnoea, particularly in certain 
environments (e.g. indoor swimming), may be detrimental to the respiratory health of 
athletes. In this respect, it has been argued that exercise itself may actually cause airway 
‘injury’ in athletes (13); prompting the development of airway dysfunction and 
respiratory symptoms. Regardless of the underlying mechanisms, it is apparent that 
more could be done to protect athletes from developing airways disease (i.e. by 
reducing exposure to irritant environments) (14).  
Overall these issues beg the question - who cares about elite athletes with asthma? It is 
the aim of this the article to present the case of why this is an important area of 
respiratory medicine. The review describes the characteristics of asthma / EIB in 
athletes and highlights the current state of knowledge in terms of the best way to detect 
and manage asthma in elite athletes.  
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WHY CARE ABOUT ASTHMA IN ELITE ATHLETES? 
It is generally accepted that for a condition to be considered clinically ‘relevant’ and of 
interest, the condition should: (i) be prevalent; (ii) have an impact on an affected 
individual; (iii) be accurately diagnosed and finally (iv) have effective treatment. There 
is a now a good body of published evidence to provide relevant support for each of 
these considerations with regards to asthma in the athletic population. The following 
section will address these criteria in turn. 
(i) Prevalence  
A considerable quantity of published data now exists detailing the prevalence of asthma 
and EIB in athletes (Table 1). The prevalence estimates vary significantly dependent 
on differences between studies in definition, diagnostic methods and techniques, 
population, subject gender and age, country, season, environment and sporting 
discipline (8, 15-17). An additional factor relates to the inclusion of studies that use 
symptoms alone for diagnosis or a combination of symptom-questionnaire and 
provocation testing. It has generally been found that in studies using symptom-based 
criteria, prevalence tended to be below 20%, whereas in those employing objective 
tests, the prevalence tended to be greater than 20% (8).  
Regardless, it is now accepted that the prevalence of asthma and EIB in elite athletes 
as a group is considerably greater than the general population and may be as much as 
five times greater in Olympians (3), (equating to approximately 8% of athletes). 
Moreover, this increased prevalence is stable when assessed longitudinally; the 
prevalence of airways disease was 21.2% and 20.7% in the British Olympic Team at 
the 2000 and 2004 Olympic Games respectively (15). 
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A particularly high prevalence of asthma is reported in athletes competing in irritant 
laden or noxious environments; for example indoor swimming or cross-country skiing. 
This may relate to the impact of a high ventilatory demand interacting with an 
environmental insult (Table 2). For instance, the prevalence of asthma in cross-country 
skiers is approximately 15-20% (3) however in contrast, the prevalence in athletes 
partaking in ski-jump competition (comparable conditions without the high ventilatory 
demand) is only 4% (14). Similar findings have been observed in pool-based sports in 
which it has been reported that 20% - 40% of Olympic swimmers have evidence of 
airway disease (3, 15), whilst data from indoor divers indicates a prevalence of merely 
~4% (IOC Independent Asthma Panel, 2002-2011). The prevalence of EIB in athletes 
performing sports that require neither a high-ventilatory demand, nor are performed in 
noxious environments (e.g. table tennis and shooting) is likely to be similar to that 
expected in the general population (3, 15). 
Accordingly, there is an evolving literature examining the role of noxious environments 
in causing an insult or ‘injury’ to the airways (13, 14, 18). Indeed when airway samples 
are studied from certain athletic groups (e.g. cross-country skiiers) there is evidence of 
pathobiological damage that has a pattern akin to a biological injury (19, 20) (Figure 
1).   
(ii) Impact of the condition  
In the athletic population, the impact or consequence of a diagnosis of asthma can be 
considered two-fold; firstly and perhaps most importantly in terms of impact on health 
and secondly on athletic performance.  
The health impact of asthma is typically considered by evaluating the consequences of 
the condition on quality of life but also morbidity (e.g. exacerbations) and mortality. 
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There currently is a paucity of data specifically evaluating these outcomes in athletes 
with asthma. Moreover, data from a longitudinal study evaluating the lifetime 
occurrence and impact of asthma indicates that a prior diagnosis of asthma in former 
athletes had no long-term consequence (21). In support of this, more recent work 
reveals that airways hyper-reactivity witnessed in certain groups of athletes (e.g. 
swimmers) is a transient phenomenon that improves within a short period of training 
cessation (22).    
This acknowledged, one study reported that a high proportion of asthma-related deaths 
occur in elite or competitive athletes (57%) in close association with a sporting event 
(23). A further study revealed that asthma was a significant risk for unexplained death 
in young athletically fit adults (24).  
It is recognised that athletes are generally more likely to report coryzal symptoms i.e. 
those typically associated with upper respiratory tract infections (URTI) (25, 26). It has 
been proposed that the relative risk of developing URTI symptoms may be heightened 
during periods of prolonged, high-intensity physical activity (i.e. elite endurance 
athletes).  
In a study evaluating underlying cause(s) for recurrent infection in athletes, a new 
diagnosis and/or the presence of poorly controlled asthma was found to be a common 
explanation (13% of athletes investigated) (27). Differentiating an infective from non-
infective aetiology of respiratory tract symptoms in athletes however is difficult given 
the overlap between symptoms; i.e. symptoms are non-specific and may relate to drying 
of the airway mucosal surfaces (28). Thus a definitive association between asthma and 
a heightened prevalence of respiratory tract infection has yet to be established. 
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In the elite athletic population a crucial consideration is the impact of asthma or EIB on 
athletic performance. Several studies have now specifically examined this issue 
although it remains an area of active research.  
Stensrud et al. (29) reported that for athletes with EIB, exercising in a humid 
environment (19.9ºC and 95% relative humidity) improved exercise capacity in 
compared to training in normal ambient conditions (20.2ºC and 40% relative humidity). 
Moreover, they also showed that exercise performance in a cold environment was 
diminished in this population (30).  
Several studies have evaluated the influence of asthma treatment on performance. In 
healthy individuals without evidence of airways disease, it is now established that 
inhaled asthma medication, when administered at standard therapeutic doses, has no 
impact on the athletic performance (31). However in athletes with EIB, Brukner and 
colleagues found that regular inhaled asthma preventative medication (32) increased 
peak oxygen uptake in a small number (n=12) of football players. 
Despite this, we (33) and other investigators (34) have failed to find any impact of 
treating EIB on performance in a sport-specific exercise test. Moreover, Sonna et al. 
(35) screened a cohort of US Army recruits and found that EIB did not hinder physical 
performance during basic training; peak oxygen uptake levels and Army Physical 
Fitness Test scores were not significantly different between individuals with and 
without EIB.  
Overall, key differences in study methodologies employed continue to make it difficult 
to draw robust conclusions regarding EIB and performance in athletes and further work 
is needed in this area. 
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(iii) Diagnosis 
Extensive investigation over the past 30 years has highlighted an important yet often 
overlooked fact in the field of EIB in athletes. That is, that symptoms correlate poorly 
with objective evidence of exercise associated airway narrowing (7, 11, 36). This poor 
association has been repeatedly demonstrated in athletes from a broad range of sporting 
disciplines and acts to limit the accuracy of a symptom-based method for diagnosis. 
Indeed Rundell et al. (36) concluded that basing a diagnosis of asthma or EIB on clinical 
symptoms alone in an athlete was likely to be as (im) precise as a coin toss. 
The reason for this discrepancy remains to be determined but may relate to a high 
prevalence of conditions that mimic asthma (12). In this respect a recent study (7) 
indicated that a high proportion of young athletes with exercise associated dyspnoea 
develop a transient narrowing that occurs at the level of the larynx causing the 
development wheeze and dyspnoea; termed exercise-induced laryngeal obstruction 
(EILO). In this study, athletes referred with dyspnoea completed a comprehensive 
assessment of their lung function, bronchial hyper-reactivity and airway inflammation. 
They also completed a nasendoscopic evaluation of their laryngeal movement - 
recorded continuously during exercise. Of the 88 athletes completing assessment, 
approximately one third had evidence of EILO as an explanation for their exercise-
related symptoms. It is important to note that the majority of these athletes were taking, 
or had previously been prescribed, inhaled asthma therapy and that it was not possible 
to differentiate those with or without EILO on the basis of clinical features alone.  
This finding has important diagnostic and treatment implications and highlights a 
problem for physicians encountering athletes who have unexplained symptoms and/or 
symptoms that are ‘refractory’ to treatment. Athletes are often misdiagnosed as having 
‘asthma’ following a diagnostic assessment based on clinical features alone (i.e. without 
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objective test confirmation) (6, 11). This is true even at the elite level of sport, where 
athletes are often labelled from an early stage in their career and on the basis of tests 
with a poor predictive value (e.g. peak flow monitoring) (4, 11).   
The role of clinical assessment in this context should simply be to focus evaluation on 
features supporting a diagnosis of asthma, but with consideration for alternative 
diagnoses (e.g. cardiac pathology) (37). A secure diagnosis then depends on 
confirmatory investigation (proposed assessment algorithm is presented in Figure 2).  
It has been argued that a sports-specific exercise field-test, simulating the exercise 
environment and demonstrating a reduction in airflow, represents the true ‘‘gold-
standard’’ method for making a diagnosis of EIB. However exercise challenge tests are 
not recommended as a first line investigation given their poor sensitivity for diagnosis 
and difficulty to perform reliably (38).  
A bronchial provocation challenge is therefore often necessary to establish evidence of 
variable airflow obstruction, i.e. to demonstrate airway narrowing in response to a 
provocation that mimics exercise (e.g. dry, cold gas). More specifically, an athlete 
performs serial spirometry tests before and following a challenge; typically looking for 
a 10% fall in forced expiratory volume (FEV1) from baseline values (39). The 
International Olympic Committee currently favor eucapnic voluntary hyperpnoea 
(EVH) testing as the gold-standard test to accurately diagnose airway dysfunction in 
athletes. However, alternative accepted diagnostic challenges include bronchodilator 
reversibility and laboratory/field exercise testing, methacholine, saline or dry powder 
mannitol challenges (40). 
(iv) Treatment 
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The treatment of asthma in athletes is well established and is in the most part 
straightforward and effective (41). Both pharmacological and non-pharmacological 
therapies play an important role in management.  
In terms of non-pharmacological management, it is recommended that athletes should 
perform a dedicated warm-up (i.e. bursts of high-intensity exercise interspersed with 
periods of low-intensity exercise) (42) to take potential advantage of the ‘refractory 
period’; defined as a period following warm-up during which further vigorous exercise 
results in significantly less severe or an absence of airway narrowing. Strategies to 
humidify the inspired air (e.g. face muffle) may also prove beneficial (43). Other studies 
have highlighted the importance of dietary manipulation as an adjunctive intervention 
(41) .  
Pharmacological therapies evaluated and shown to protect against EIB include inhaled 
beta-2 agonists, inhaled corticosteroids, cromolyn compounds and leukotriene 
modifiers. An inhaled short acting beta-2 agonist administered prior to exercise is 
usually effective in negating EIB and forms the mainstay of pharmacological treatment 
(41). Beyond this however, there is a lack of consensus with regards the optimum 
choice, timing of initiation or dose of regular preventative medication. It has been 
recommended that an athlete who has asthma symptoms outside the setting of exercise 
or who is using beta-2 agonist medication (i.e. greater than three times per week) should 
be treated with anti-inflammatory agent; e.g. regular inhaled corticosteroid or an oral 
leukotriene antagonist. However for an elite athlete it is commonplace to train twice 
daily and as such this advice is effectively obsolete. The current best evidence with 
regards treatment of EIB is presented in the recent American Thoracic Society 
Guidelines (41).  
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Clinicians should also be aware that some medications used for the treatment of asthma 
are prohibited for use by the World Anti-Doping Agency. The list of prohibited asthma 
medications has diminished considerably over the past five years however there remain 
notable exceptions and it is therefore advisable to view www.globaldro.org or consult 
with the relevant national anti-doping agency to ensure an athlete remains compliant 
with regulations from their sporting body.  
WHO CURRENTLY CARES FOR ELITE ATHLETES WITH ASTHMA?  
In the UK, it is common for primary care physicians to regularly encounter patients 
with exercise-related respiratory symptoms (4). Moreover, in a one-year period (2008-
2009), approximately 70% of applications for asthma medication ‘therapeutic use 
exemption’ forms (i.e. the paperwork to permit an elite ‘national standard’ or 
professional athlete to use asthma medication) was submitted by primary care 
physicians (personal communication N.Wojek – UK Anti-Doping).  
It is therefore of concern, that evidence suggests that the diagnosis and treatment of 
asthma / EIB in athletes is often not in keeping with guideline recommendations. Indeed 
in a questionnaire survey of primary care UK physicians, one third indicated that they 
would initiate treatment based on clinical information alone (4). Moreover, although 
over two-thirds of primary care physicians chose investigation as the initial course of 
action, the tests selected (e.g. PEFR on exercise (44%) and resting spirometry pre-and 
post- bronchodilator (35%)) are recognised to have poor diagnostic precision. Similar 
findings were apparent in a study evaluating primary care physicians approach to EIB 
in the US (6). Overall, these findings have important implications regarding the quality 
of management of an athlete’s respiratory health.  
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It could be argued that all elite athletes, and certainly members of an Olympic squad, 
should be ‘screened’ for airway dysfunction. We have previously discussed the 
implications of implementing a widespread EIB screening policy in athletes 
highlighting the benefit versus harm of such a policy (1). One important consequence 
to be considered in view of a heightened focus on diagnostic accuracy is the risk of 
over-diagnosis (1, 8). In this respect it is becoming increasingly apparent that there 
exists a population of athletes whom are asymptomatic, yet have been labelled as 
having ‘asthma’ on the basis of airways hyper-reactivity; i.e. detected from a positive 
bronchoprovocation test (44). The impact of a diagnosis of ‘asthma’ in this population, 
both for the health and performance of an athlete remains to be established. On balance 
therefore general screening for asthma in athletes is not recommended however, this 
may be appropriate in high risk sporting groups (e.g. swimmers) (41).  
Overall, it could be argued that given the complexities regarding diagnosis and 
surveillance it is ideal that athletes presenting with respiratory symptoms are referred 
to a sports physician or respiratory physician with expertise in this area.    
WHO CARES ABOUT RESEARCHING ASTHMA IN ATHLETES? 
There has been a steady increase in the number of manuscripts published in the field of 
asthma and EIB in athletes over the past 20 years (Figure 3). Recent work has focussed 
on accuracy of clinical diagnosis, differential diagnosis, the impact of detraining on 
airways hyper-reactivity, presence of airway pathology and airway injury.  
It remains however the experience of many researchers studying EIB in athletes in 
Europe (variety of personal communications) that research in this field remains under-
funded by the major medical grant awarding bodies. This may relate to a perception 
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from the funding bodies, that when compared with other respiratory diseases the impact 
of airway dysfunction in a relatively fit, young population is of low priority.  
It remains however that exercise is the one of the most commonly reported symptom 
triggers in individuals with asthma and dyspnoea on exertion is a prominent and 
disabling clinical characteristic of the disease (45). Undoubtedly, research in the field 
of EIB in young fit individuals has been of translational benefit for the general 
asthmatic population. Furthermore recent work evaluating airway injury and potential 
mechanisms to protect the airway of asthmatic athletes will be of likely benefit to the 
general asthmatic population.  
Conclusion – time to care more about asthma in athletes 
The purpose of this article was to present the case for why it is important to care about 
asthma in elite athletes. The evidence presented highlights a wealth of data that 
indicates that asthma / EIB in athletes is highly prevalent, has an important potential 
impact on their health and performance and can be diagnosed and treated effectively. 
Despite this, the review also details important deficiencies that remain in the current 
state of knowledge in this field (Table 3), supporting the fact that focus should remain 
on this condition with the aim of optimising respiratory care in athletes. 
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TABLE FOOTNOTES 
Table 1. Studies evaluating the prevalence of Asthma in Elite Athletes 
Definition of abbreviations: EVH, Eucapnic voluntary hyperpnoea; MT, methacholine 
test; LT, laboratory exercise test; FT, field test; SS, sport specific exercise challenge; 
FEV1, forced expiratory volume in one second; PD20, provocative dose (causing a fall 
in 20% in FEV1); PC20, provocative concentration (causing a fall in 20% in FEV1).  
 
Table 2. Environmental exposure during sport and impact on athlete airway 
health 
Definition of abbreviations: AHR, Airway hyper-responsiveness. 
 
Table 3. Asthma in Elite Athletes – Summary of key criteria and research needs 
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FIGURE LEGENDS  
Figure 1. Impact of exercise hyperpnoea on airway health in susceptible athletes. 
Adapted from Anderson and Kippelen (46) . 
 
Figure 2. Approach to diagnostic assessment and management of asthma in elite 
athletes. Reproduced with permission from Hull et al. (12) 
 
Figure 3. Research publications in exercise-induced bronchoconstriction published on 
PubMed (National Institutes of Health) between 1992-2012 – using search terms: 
exercise-induced asthma; exercise-induced bronchoconstriction; asthma; in 
combination with athletes.  
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Table 2.  
First Author  Year Population Number (n) Protocol Diagnostic criteria Prevalence (%) 
Weiler (47) 1986 Student football (F) and basketball (B) based athletes 172 MT PC20 <25mg
.ml-1 
50% (F) 
25% (B) 
Wilber  (48) 1986 Olympic winter sport athletes 170 FT >10% fall in FEV1 23% 
Larsson  (49) 1993 Cross-Country Skiers 42 MT PC20 > 10th Centile 55% 
Sue-Chu  (50) 1996 Cross-Country Skiers 171 MT PD20 <1800μg 14 – 43% 
Mannix  (51) 1996 Figure skaters 124 SS >10% fall in FEV1 35% 
Helenius  (52) 1996 National standard runners 32 FT >10% fall in FEV1 25% 
Helenius (53)   1998 National standard swimmers 29 HT >10% fall in FEV1 48% 
Helenius  (54) 1998 National standard runners 58 FT >10% fall in FEV1 9% (26% if 2 SD from control group) 
Leuppi  (55) 1998 National standard ice hockey (IH) and floorball (FB) 50 MT, FT PC20 <2mg
.ml-1 
MT = 35 (IH), 21 (FB) 
FT = 11(IH), 4 (FB) 60% 
Mannix  (56) 1999 Figure skaters 29 SS, EVH >10% fall in FEV1 55% 
Ross  (57) 2000 Professional football players 34 Reversibility >12% rise in FEV1 56% 
Langdeau  (58) 2000 Athletes from a variety of sporting backgrounds 100 MT PC20 <16mg
.ml-1 49% 
Rundell  (36) 2001 Elite winter sport athletes 158 SS >10% fall in FEV1 26% 
Rundell  (59) 2004 National standard female Ice Hockey Players 43 SS >10% fall in FEV1 21% 
Dickinson   (15) 2005 Olympic standard athletes Summer Sports 77 EVH >10% fall in FEV1 21-44% 
Durand (60) 2005 Ski-Mountaineers - Skiing 31 SS >10% fall in FEV1 50% 
Verges (61) 2005 
National standard athletes 
Skiing, Triathlon (Tri) 
39 LT, MT 
>10% fall in FEV1, 
 
41% (Ski), 40 % (Tri) 
Bougault  (62) 2009 
High-level (provincial to international) 
competitive swimmers and cold air 
athletes 
64 MT PC20 <16mg.ml-1 
69% (Swimmers) 
28% (Cold air athletes) 
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Sporting Environment 
Environmental 
Irritant 
Impact on airway health 
Pool-based sport 
(e.g. swimming, water polo) 
Chlorine derivatives (e.g. sodium 
hypochlorite and chlorinated isocyanuric 
acids) 
Repeated exposure to chlorine compounds in swimming 
pools during training and competition implicated in the 
increased prevalence of bronchial hyper-responsiveness, 
airway inflammation and structural remodelling processes  
Indoor Winter sport 
(e.g. speed skating, ice hockey) 
Pollution related particulate matter Daily high ventilation rates with cold dry air and ice re-surfacing pollutants implicated in airway injury. 
Outdoor Winter Sport 
(e.g. Cross-country skiing) 
Cold / dry air - inhaled at high volumes 
Environmental stress to the proximal and distal airways 
Results in the development of respiratory symptoms, airway 
inflammation, AHR, epithelial injury and structural 
remodelling. 
Indoor Summer sport 
(e.g. track cycling) 
Humid / dry air 
Aeroallergens 
Stadia dusts / particulate matter 
Aeroallergens (dog, cat and mite) identified within indoor 
arenas exceeding the threshold for allergic symptoms and/or 
sensitisation. 
 
Outdoor Summer sport 
(e.g. cycling, rowing, running) 
 
 
Environmental pollutants (e.g. sulphur 
dioxide), ozone, aeroallergens) 
 
 
Exposure to high levels of environmental pollutants / 
irritants / allergens when combined with prolonged exercise 
hyperpnoea may provoke respiratory tract infection, lung 
function deterioration and promote airway inflammation. 
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Table 3.  
Criteria  Summary / key considerations Further research  
Prevalence 
Highly prevalent in athletes partaking in 
endurance sports in certain environments 
(e.g. swimmers). 
Explore longitudinal 
changes in occurrence of 
asthma / EIB from youth 
to professional / elite 
level sport. 
Impact  
Health 
Evidence of increase mortality associated 
with asthma in some studies. Increased 
prevalence of cough. Some evidence of 
heightened propensity to upper 
respiratory tract infection. 
Evaluate risk of infection 
/ loss of training days in 
athletes with EIB. 
Performance 
 
Some evidence of improved aerobic 
capacity when EIB treated. 
 
Work needed to explore 
impact on sport-specific 
exercise performance in 
asymptomatic athletes 
with EIB. 
Diagnosis 
Symptoms correlate poorly with 
objective evidence of airway narrowing. 
 
Bronchoprovocation testing therefore 
recommended to ensure diagnosis is 
secure. 
Establish place of 
exhaled biomarkers in 
diagnosis and 
monitoring.  
Evaluation of approach to 
diagnosis that permits 
simultaneous evaluation 
of most important 
differential diagnosis- i.e. 
laryngeal obstruction 
versus EIB 
 
Treatment 
Pharmacological and non-
pharmacological management important. 
 
Include - strategies to humidify the 
inspired air (e.g. face muffle). 
Dietary modification (i.e. omega-3 fish 
oils). 
 
Pharmacological prophylaxis to prevent 
EIB includes: beta-2 agonists, inhaled 
corticosteroids, cromolyn compounds 
and leukotriene modifiers. 
 
Impact of treatment on 
repeated 
bronchoprovocation in a 
‘real-life’ treatment trial. 
i.e. in Olympic squad 
members. 
Work needed to explore 
impact of primary 
prevention on long-term 
airway health (e.g. face 
muffles in cross-country 
skiers). 
 20
Figure 1. 
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Figure 2. 
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Figure 3. 
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